Two oral drugs with radiation for newly diagnosed high-grade glioma
Part of Cancer clinical trials.
This study tests whether two oral medications (avutometinib and defactinib) are safe and possible to take together with standard radiation therapy in people newly diagnosed with high-grade glioma. It may help control the tumor when used early in treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a recent diagnosis of a high-grade glioma (a type of brain tumor) and have not had any previous treatment for it.
- Your doctor plans to give you standard radiation therapy for about 6 weeks.
- You are generally able to care for yourself (score of 70% or higher on a performance scale).
- You do not have any known brain or heart problems that would make the treatment risky.
- You are willing to take oral medications twice a day and follow the study schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) for people with advanced lung adenocarcinoma that has a specific gene mutation (LKB1) and has stopped responding to prior immunotherapy and chemotherapy. The goal is to see if this new combination can shrink tumors or slow cancer growth.
This trial tests two oral drugs, avutometinib and defactinib, in people with aggressive brain tumors like glioblastoma. The goal is to see if this combination can shrink tumors or stop them from growing.
This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.
This Phase 1 study tests whether adding an immune therapy called retifanlimab to radiation (and a chemotherapy medicine called temozolomide, in some parts of the study) is safe and helpful for newly diagnosed glioblastoma patients after surgery with carmustine wafers. It aims to see how well this combination controls the cancer and what side effects are expected.
This trial tests a new two-part treatment (DB107-RRV and DB107-FC) combined with radiation, with or without the chemotherapy drug temozolomide, for people with newly diagnosed high-grade glioma. It aims to see if this approach is safe and effective.
This study tests a new medicine (MT-125) combined with standard radiation and chemotherapy for people with newly diagnosed glioblastoma that has a specific gene change (MGMT methylated). The goal is to see if it is safe and tolerable, and to look for early signs it might help.
Hear when a new MGMT-unmethylated Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.